National
Has the gay agenda been shelved?
Further action on LGBT bills looking less likely this Congress
On the long-stalled Employment Non-Discrimination Act, U.S. Rep. Barney Frank said ‘we’re still trying to figure out a way to get that done.’ (Washington Blade photo by Michael Key)
The limited time remaining in the legislative calendar for this Congress is raising questions about whether lawmakers will pass any further pro-LGBT bills before year’s end — and whether it will be politically feasible to pass such bills next year.
Congress advanced LGBT-related legislation last year when it passed hate crimes protections. This year, a measure that would lead to repeal of “Don’t Ask, Don’t Tell” seems likely to reach President Obama’s desk.
Still, some LGBT activists and voters are frustrated that Congress has taken no action to advance the Employment Non-Discrimination Act. Supporters of the legislation have said several times a vote was imminent, but no such action has yet been taken.
Other pending measures include the Domestic Partnership Benefits & Obligations Act, which would allow LGBT federal workers to receive spousal benefits for their same-sex partners, as well as the Uniting American Families Act and repeal of the Defense of Marriage Act.
Further complicating the situation is the specter of reduced Democratic majorities in the next Congress — or even a Republican takeover — and whether measures unaddressed this year would be viable in 2011.
Despite the limited time remaining this year, some LGBT rights supporters are hopeful that Congress will move forward with additional legislation. U.S. Rep. Barney Frank (D-Mass.), a gay lawmaker and House sponsor of ENDA, expressed optimism about the bill passing the House this year.
“That’s going to be next thing we’ll turn our attention to,” Frank said. “We have the speaker’s support and we’re still trying to figure out a way to get that done.”
The scheduling for a House vote on ENDA remains an issue. House Speaker Nancy Pelosi earlier told the Blade that a House vote on ENDA wouldn’t occur until Congress finishes legislative action on “Don’t Ask, Don’t Tell.”
Drew Hammill, a Pelosi spokesperson, said ENDA remains “a top priority for the speaker,” but a vote on the bill before work on “Don’t Ask, Don’t Tell” is complete “jeopardizes both initiatives.”
“Until then, we should encourage the Senate to develop a course for ENDA to ensure that when the House passes the legislation, the Senate can move quickly to send the legislation to the president’s desk,” Hammill said.
Frank said efforts toward repealing “Don’t Ask, Don’t Tell” displaced ENDA in the batting order for Congress because the fiscal year 2011 defense authorization bill came to lawmakers before a vote could happen on ENDA.
“If the defense authorization hadn’t come up earlier, we might have been able to do ENDA first,” he said.
Frank noted that he thinks the votes exist in the House to pass a trans-inclusive ENDA, but he wouldn’t give a timetable for when the legislation would move forward in Congress because he didn’t want to tip off opponents of the bill.
Michael Cole, a Human Rights Campaign spokesperson, said a House vote on ENDA is among the pro-LGBT items his organization has pressed for in the time remaining in this year’s legislative calendar.
“We’re certainly interested in seeing the House take a vote on ENDA,” Cole said. “We’ve been advocating for that for a long time, and as recess comes, we’ll be doing a lot of work to make sure our members are getting in touch with members of Congress to push for a vote on it.”
But if the House manages to pass ENDA this year, getting the legislation through the Senate remains a significant challenge. Sources have said 60 votes are lacking in the Senate to overcome a filibuster on the legislation. Also, because the Senate allows non-germane amendments, opponents of the bill could attach additional measures in an attempt to block its passage.
Still, Frank said he believes passage of ENDA in the Senate remains a possibility.
“If you ask them if they think they can pass it, they’ll say ‘no,’ so the important thing to do is for us [in the House] to try [to] pass it and send it over there, so they can’t just avoid it,” Frank said.
Activists also foresee a possibility of passing the Domestic Partnership Benefits & Obligations Act before year’s end.
Cole said the legislation, as well as the Tax Equity for Health Plan Beneficiaries Act, which would eliminate the tax penalty paid on employer-provided health insurance for domestic partners, could be made part of upcoming omnibus authorization or appropriations bills.
“We’re following what the plans appear to be on the Hill to see how we might be able to get those pieces of legislation [advanced] as part of them,” Cole said.
Frank also acknowledged the possibility of passing the Domestic Partnership Benefits & Obligations Act and said that legislation is “in serious conversation.”
Still, Frank noted the bill comes with a price tag — estimated at one time by the U.S. Office of Personnel Management to be $56 million a year — and that concerns associated with raising the federal deficit may cause problems in passing the bill.
Frank said finding a way to offset the legislation’s cost remains an issue for the Domestic Partnership Benefits & Obligations Act and “we have to find a way to pay for that.”
Whatever progress this Congress makes on passing pro-LGBT bills, recent polls are casting doubts on whether enough Democratic lawmakers will retain their seats next Congress to pass such bills.
Several recent polls have shown considerable opposition toward Democrats and the Obama administration as persistent unemployment and concerns about government spending linger across the country.
White House Press Secretary Robert Gibbs gained media attention and inspired consternation among Democratic House members when, during an appearance earlier this month on NBC’s “Meet the Press,” he said Republicans could regain control of the House.
“I think people are going to have a choice to make in the fall,” Gibbs said. “But I think there’s no doubt there are enough seats in play that could cause Republicans to gain control. There’s no doubt about that.”
Larry Sabato, a political scientist at the University of Virginia, is projecting that Republicans will win seven seats in the Senate and 32 seats in House after the election.
Because of this potential shift, Sabato said passage of more pro-LGBT bills next Congress is unlikely if it doesn’t happen this year.
“If these pieces of legislation don’t pass now, when both houses have swollen Democratic majorities, they certainly aren’t going to pass in the next Congress, when Democrats will have narrow majorities, or even be in the minority,” Sabato said.
Sabato said the loss of a half-dozen Democratic seats in the Senate could be enough to “kill these bills” entirely in the next Congress because proponents wouldn’t be able to find 60 votes to thwart a filibuster.
But Frank said the possibility of passing more pro-LGBT legislation in a future Congress is unknown because the fallout of the November elections is yet to be seen.
“I don’t think there’s any question there will be Republican gains in both chambers,” he said. “But what kind of gains? How much? Three senators? Eight senators? Fifteen representatives? Thirty-five representatives?”
Frank also said some members of Congress that would lose in the upcoming election wouldn’t “be supportive of ENDA anyway.”
Additionally, he said Congress could more easily take up other pro-LGBT bills in the future after items like hate crimes and “Don’t Ask, Don’t Tell” are off the table.
“To some extent, the more you have to work on, the harder it is to do any one of them,” he said.
Cole said although no one knows what the future holds for support for pro-LGBT legislation after year’s end, he noted several supportive incumbents are in danger of losing their seats.
“The thing to keep in mind, though, is cobbling together a pro-LGBT majority for any piece of legislation has never been a slam dunk,” Cole said. “It’s not necessarily about party affiliation — it’s about people who have taken stances toward equality measures.”
Federal Government
Holiday week brings setbacks for Trump-Vance trans agenda
Federal courts begin to deliver end-of-year responses to lawsuits involving federal transgender healthcare policy.
While many Americans took the week of Christmas to rest and relax, LGBTQ politics in the U.S. continued to shift. This week’s short recap of federal updates highlights two major blows to the Trump-Vance administration’s efforts to restrict gender-affirming care for minors.
19 states sue RFK Jr. to end gender-affirming care ban
New York Attorney General Letitia James announced on Tuesday that the NYAG’s office, along with 18 other states (and the District of Columbia), filed a lawsuit to stop U.S. Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. from restricting gender-affirming care for minors.
In the press release, Attorney General James stressed that the push by the Trump-Vance administration’s crusade against the transgender community — specifically transgender youth — is a “clear overreach by the federal government” and relies on conservative and medically unvalidated practices to “punish providers who adhere to well-established, evidence-based care” that support gender-affirming care.
“At the core of this so-called declaration are real people: young people who need care, parents trying to support their children, and doctors who are simply following the best medical evidence available,” said Attorney General James. “Secretary Kennedy cannot unilaterally change medical standards by posting a document online, and no one should lose access to medically necessary health care because their federal government tried to interfere in decisions that belong in doctors’ offices. My office will always stand up for New Yorkers’ health, dignity, and right to make medical decisions free from intimidation.”
The lawsuit is a direct response to HHS’ Dec. 18 announcement that it will pursue regulatory changes that would make gender-affirming health care for transgender children more difficult, if not impossible, to access. It would also restrict federal funding for any hospital that does not comply with the directive. KFF, an independent source for health policy research, polling, and journalism, found that in 2023 federal funding covered nearly 45% of total spending on hospital care in the U.S.
The HHS directive stems directly from President Donald Trump’s Jan. 28 Executive Order, Protecting Children From Chemical and Surgical Mutilation, which formally establishes U.S. opposition to gender-affirming care and pledges to end federal funding for such treatments.
The American Medical Association, the nation’s largest and most influential physician organization, has repeatedly opposed measures like the one pushed by President Trump’s administration that restrict access to trans health care.
“The AMA supports public and private health insurance coverage for treatment of gender dysphoria and opposes the denial of health insurance based on sexual orientation or gender identity,” a statement on the AMA’s website reads. “Improving access to gender-affirming care is an important means of improving health outcomes for the transgender population.”
The lawsuit also names Oregon, Washington, California, Colorado, Connecticut, Delaware, the District of Columbia, Illinois, Maine, Maryland, Massachusetts, Michigan, Minnesota, New Mexico, Pennsylvania, Rhode Island, Vermont, and Wisconsin as having joined New York in the push against restricting gender-affirming care.
At the HHS news conference last Thursday, Jim O’Neill, deputy secretary of the department, asserted, “Men are men. Men can never become women. Women are women. Women can never become men.”
DOJ stopped from gaining health care records of trans youth
U.S. District Judge Cathy Bissoon blocked an attempt by the Department of Justice (DOJ) to gain “personally identifiable information about those minor transgender patients” from the University of Pittsburgh Medical Center (UPMC), saying the DOJ’s efforts “fly in the face of the Supreme Court.”
Journalist Chris Geidner originally reported the news on Dec. 25, highlighting that the Western District of Pennsylvania judge’s decision is a major blow to the Trump-Vance administration’s agenda to curtail transgender rights.
“[T]his Court joins the others in finding that the government’s demand for deeply private and personal patient information carries more than a whiff of ill intent,” Bissoon wrote in her ruling. “This is apparent from its rhetoric.”
Bissoon cited the DOJ’s “incendiary characterization” of trans youth care on the DOJ website as proof, which calls the practice politically motivated rather than medically sound and seeks to “…mutilate children in the service of a warped ideology.” This is despite the fact that a majority of gender-affirming care has nothing to do with surgery.
In United States v. Skrmetti, the Supreme Court ruled along party lines that states — namely Tennessee — have the right to pass legislation that can prohibit certain medical treatments for transgender minors, saying the law is not subject to heightened scrutiny under the Equal Protection Clause of the Fourteenth Amendment because it does not involve suspect categories like race, national origin, alienage, and religion, which would require the government to show the law serves a compelling interest and is narrowly tailored, sending decision-making power back to the states.
“The government cannot pick and choose the aspects of Skrmetti to honor, and which to ignore,” Judge Bissoon added.
The government argued unsuccessfully that the parents of the children whose records would have been made available to the DOJ “lacked standing” because the subpoena was directed at UPMC and that they did not respond in a timely manner. Bissoon rejected the timeliness argument in particular as “disingenuous.”
Bissoon, who was nominated to the bench by then-President Obama, is at least the fourth judge to reject the DOJ’s attempted intrusion into the health care of trans youth according to Geidner.
A Wider Bridge on Friday announced it will shut down at the end of the month.
The group that “mobilizes the LGBTQ community to fight antisemitism and support Israel and its LGBTQ community” in a letter to supporters said financial challenges prompted the decision.
“After 15 years of building bridges between LGBTQ communities in North America and Israel, A Wider Bridge has made the difficult decision to wind down operations as of Dec. 31, 2025,” it reads.
“This decision comes after challenging financial realities despite our best efforts to secure sustainable funding. We deeply appreciate our supporters and partners who made this work possible.”
Arthur Slepian founded A Wider Bridge in 2010.
The organization in 2016 organized a reception at the National LGBTQ Task Force’s Creating Change Conference in Chicago that was to have featured to Israeli activists. More than 200 people who protested against A Wider Bridge forced the event’s cancellation.
A Wider Bridge in 2024 urged the Capital Pride Alliance and other Pride organizers to ensure Jewish people can safely participate in their events in response to an increase in antisemitic attacks after Hamas militants attacked Israel on Oct. 7, 2023.
The Jewish Telegraphic Agency reported authorities in Vermont late last year charged Ethan Felson, who was A Wider Bridge’s then-executive director, with lewd and lascivious conduct after alleged sexual misconduct against a museum employee. Rabbi Denise Eger succeeded Felson as A Wider Bridge’s interim executive director.
A Wider Bridge in June honored U.S. Rep. Debbie Wasserman Schultz (D-Fla.) at its Pride event that took place at the Capital Jewish Museum in D.C. The event took place 15 days after a gunman killed two Israeli Embassy employees — Yaron Lischinsky and Sarah Milgrim — as they were leaving an event at the museum.
“Though we are winding down, this is not a time to back down. We recognize the deep importance of our mission and work amid attacks on Jewish people and LGBTQ people – and LGBTQ Jews at the intersection,” said A Wider Bridge in its letter. “Our board members remain committed to showing up in their individual capacities to represent queer Jews across diverse spaces — and we know our partners and supporters will continue to do the same.”
Editor’s note: Washington Blade International News Editor Michael K. Lavers traveled to Israel and Palestine with A Wider Bridge in 2016.
The White House
‘Trump Rx’ plan includes sharp cuts to HIV drug prices
President made announcement on Friday
President Donald Trump met with leaders from some of the world’s largest pharmaceutical companies at the White House on Friday to announce his new “Trump Rx” plan and outline efforts to reduce medication costs for Americans.
During the roughly 47-minute meeting in the Roosevelt Room, Trump detailed his administration’s efforts to cut prescription drug prices and make medications more affordable for U.S. patients.
“Starting next year, American drug prices will come down fast, furious, and will soon be among the lowest in the developed world,” Trump said during the meeting. “For decades, Americans have been forced to pay the highest prices in the world for prescription drugs by far … We will get the lowest price of anyone in the world.”
Trump signed an executive order in May directing his administration “to do everything in its power to slash prescription drug prices for Americans while getting other countries to pay more.”
“This represents the greatest victory for patient affordability in the history of American health care, by far, and every single American will benefit,” he added.
Several pharmaceutical executives stood behind the president during the announcement, including Sanofi CEO Paul Hudson, Novartis CEO Vas Narasimhan, Genentech CEO Ashley Magargee, Boehringer Ingelheim (USA) CEO Jean-Michel Boers, Gilead Sciences CEO Dan O’Day, Bristol Myers Squibb General Counsel Cari Gallman, GSK CEO Emma Walmsley, Merck CEO Robert Davis, and Amgen Executive Vice President Peter Griffith.
Also in attendance were Health and Human Services Secretary Robert F. Kennedy Jr., Commerce Secretary Howard Lutnick, Centers for Medicare and Medicaid Services Administrator Mehmet Oz, and Food and Drug Administration Commissioner Marty Makary.
Under the Trump Rx plan, the administration outlined a series of proposed drug price changes across multiple companies and therapeutic areas. Among them were reductions for Amgen’s cholesterol-lowering drug repatha from $573 to $239; Bristol Myers Squibb’s HIV medication reyataz from $1,449 to $217; Boehringer Ingelheim’s type 2 diabetes medication jentadueto from $525 to $55; Genentech’s flu medication xofluza from $168 to $50; and Gilead Sciences’ hepatitis C medication epclusa from $24,920 to $2,425.
Additional reductions included several GSK inhalers — such as the asthma inhaler advair diskus 500/50, from $265 to $89 — Merck’s diabetes medication januvia from $330 to $100, Novartis’ multiple sclerosis medication mayzent from $9,987 to $1,137, and Sanofi’s blood thinner plavix from $756 to $16. Sanofi insulin products would also be capped at $35 per month’s supply.
These prices, however, would only be available to patients who purchase medications directly through TrumpRx. According to the program’s website, TrumpRx “connects patients directly with the best prices, increasing transparency, and cutting out costly third-party markups.”
Kennedy spoke after Trump, thanking the president for efforts to lower pharmaceutical costs in the U.S., where evidence has shown that drug prices — including both brand-name and generic medications — are nearly 2.78 times higher than prices in comparable countries. According to the Pharmaceutical Research and Manufacturers of America, roughly half of every dollar spent on brand-name drugs goes to entities that play no role in their research, development, or manufacturing.
“This is affordability in action,” Kennedy said. “We are reversing that trend and making sure that Americans can afford to get the life-saving solutions.”
Gilead CEO Dan O’Day also spoke about how the restructuring of drug costs under TrumpRx, combined with emerging technologies, could help reduce HIV transmission — a virus that, if untreated, can progress to AIDS. The LGBTQ community remains disproportionately affected by HIV.
“Thank you, Mr. President — you and the administration,” O’Day said. “I think this objective of achieving the commitment to affordability and future innovation is extraordinary … We just recently launched a new medicine that’s only given twice a year to prevent HIV, and we’re working with Secretary Kennedy and his entire team, as well as the State Department, as a part of your strategy to support ending the epidemic during your term.
“I’ve never been more optimistic about the innovation that exists across these companies and the impact this could have on America’s health and economy,” he added.
Trump interjected, asking, “And that’s working well with HIV?”
“Yes,” O’Day replied.
“It’s a big event,” Trump said.
“It literally prevents HIV almost 100 percent given twice a year,” O’Day responded.
A similar anti-HIV medication is currently prescribed more than injectable form mentioned by O’Day. PrEP, is a medication regimen proven to significantly reduce HIV infection rates for people at high risk. Without insurance, brand-name Truvada can cost roughly $2,000 per month, while a generic version costs about $60 per month.
Even when medication prices are reduced, PrEP access carries additional costs, including clinic and laboratory fees, office visits, required HIV and sexually transmitted infection testing, adherence services and counseling, and outreach to potentially eligible patients and providers.
According to a 2022 study, the annual total cost per person for PrEP — including medication and required clinical and laboratory monitoring — is approximately $12,000 to $13,000 per year.
The TrumpRx federal platform website is now live at TrumpRx.gov, but the program is not slated to begin offering reduced drug prices until January.
Holiday week brings setbacks for Trump-Vance trans agenda
Your guide to D.C.’s queer New Year’s Eve parties
Long-awaited ‘Pillion’ surpasses the sexy buzz
Trump’s ‘American people derangement syndrome’
Reasons to be optimistic about 2026
Reasons to be optimistic about 2026
Long-awaited ‘Pillion’ surpasses the sexy buzz
Protecting the trans community is not optional for elected allies and candidates
Trump’s ‘American people derangement syndrome’
